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Could NICE guidance on the choice of blood pressure
lowering drugs be simplified?
Reecha Sofat and colleagues argue that prescribing advice needs updating in the light of recent
evidence that all classes of blood pressure lowering drugs are broadly equivalent
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High blood pressure is the most common modifiable cause of
cardiovascular morbidity and mortality worldwide,1 and blood
pressure lowering drugs from four major classes (angiotensin
converting enzyme (ACE) inhibitors and angiotensin receptor
blockers, β blockers, calcium channel blockers, and diuretics)
are prescribed in large volumes. Among these, treatment would
be dictated by cost or tolerability if all drugs were of similar
efficacy and safety and had an additive effect when used in
combination. However, guidance from the National Institute
for Health and Clinical Excellence (NICE) and the British
Hypertension Society emphasises differences between drug
classes and combinations in blood pressure response and clinical
outcomes.
NICE’s recommendations are based on the view that younger
patients (≤55 years) are more responsive to drugs targeting the
renin-angiotensin system than older patients; that β blockers
are less effective than the other drug classes for the prevention
of stroke; and that β blockers and diuretics lead to a clinically
important increase in the risk of type 2 diabetes. Consequently,
its 2006 guidelines gave primacy to angiotensinmodifying drugs
and calcium channel blockers, with a substantial influence on
prescribing behaviour in England and Wales (fig 1⇓).2 The
updated guidelines published last August (www.nice.org.uk/
CG127) maintain this view, but how strong is the evidence?
Stratification by age
Current NICE recommendations represent an evolution of the
view that blood pressure is best lowered with β blockers or ACE
inhibitors in patients under 55 years (in whom an activated
renin-angiotensin systemmay be an important mechanism) and
diuretics or calcium channel blockers in older patients (because
sodium retention, with suppression of the renin-angiotensin
system, may be more important). This was based primarily on
the findings of a study (n=36) that rotated young patients through
monthly treatment with each of four main classes of blood
pressure lowering drugs and assessed the effect on blood
pressure.3
By 2006, NICE had relegated β blockers to third or fourth line
therapy because of concerns about reduced protection from
stroke,2 and last year NICE dropped diuretics as a first line
option. Renin declines with age,4 and the major drug classes do
differ in their effect on the renin-angiotensin system. However,
the performance of age as a proxy for stratifying blood pressure
response or in comparison with measurement of renin
concentrations (now possible with a rapid, cheap assay) has yet
to be formally evaluated. Moreover, a meta-analysis including
data from 11 000 participants from 42 trials, which included
people younger than 55, concluded that the “blood pressure
reduction from combining drugs from these 4 classes can be
predicted on the basis of additive effects.”7 This conclusion even
included combinations of two drugs that both suppress or
activate renin.
Efficacy of β blockers
Two sources of evidence were influential in NICE’s relegation
of β blockers from first line treatment: the Anglo Scandinavian
Cardiovascular Outcomes Trial (ASCOT), published in 2005,8
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and three meta-analyses examining the efficacy of β blockers
in the prevention of cardiovascular events, published in
2005-6.9-11
ASCOTwas a randomised trial comparing an amlodipine based
treatment regimen (with addition of perindopril and then
doxazosin if required) with an atenolol based treatment regimen
(with the addition of bendroflumethazide and then doxazosin
if required) to achieve a blood pressure <140/90 mm Hg. The
trial was terminated early on the advice of the data safety
monitoring committee because of a significant treatment
difference in favour of patients randomised to the amlodipine
based regimen for two secondary end points (stroke and total
cardiovascular events). There was no difference in the primary
end point of non-fatal myocardial infarction or fatal coronary
heart disease. Blood pressure was lower in the group randomised
to amlodipine rather than atenolol by around 2.7/1.9 mm Hg.
The trialists’ analysis suggested the blood pressure difference
was insufficient to explain the disparity in event rates, but an
accompanying commentary reached the opposite conclusion.
A subsequent meta-analysis examined trials comparing β
blockers with other blood pressure lowering drugs.9 Stroke risk
was 16% higher (95% confidence interval 4% to 30%) among
patients randomised to β blockers than among those taking other
drugs. Two other meta-analyses reached similar conclusions.10 11
However, the inclusion and exclusion criteria of these
meta-analyses were not uniform. A re-analysis shows that the
pooled estimate of the comparative efficacy of β blockers for
preventing stroke is sensitive to which trials were considered
eligible (see supplementary analysis on bmj.com). Furthermore,
they did not account for blood pressure differences between the
treatment arms. The achieved blood pressure favoured the
comparator drug over β blockers in all scenarios, which may
bias the outcome in favour of the comparator drug. The blood
pressure disparity is unlikely to be because β blockers are
inherently less effective at lowering blood pressure than other
drugs 14 but rather because achieving a precisely equivalent
blood pressure reduction in two arms of a comparator trial is
extremely challenging. Nevertheless this is essential for a fair
comparison of the efficacy of two drug classes.
Two new comprehensive meta-analyses now supersede these
studies.15 16 These examined the efficacy of all major blood
pressure drug classes (not just β blockers) in the context of the
achieved reductions in blood pressure. The Blood Pressure
Treatment Trialists Collaboration, which incorporated
information from 190 606 participants across 31 treatment trials,
concluded that all classes of drug were broadly equivalent with
respect to protection from serious cardiovascular events.15 The
analysis indicated a log-linear association between blood
pressure reduction and the relative risk of events, in keeping
with predictions from observational studies. A second analysis
by Law and colleagues, which included information from 147
published trials among 464 000 participants, concluded the
protective effect of lowering blood pressure on coronary heart
disease was the same for all drug classes with two exceptions.16
Calcium channel blockers had a small class specific advantage
in protecting from stroke over all other classes. The authors
considered that this probably accounted for most of the apparent
disadvantage of β blockers in stroke protection because calcium
channel blockers had been the most common comparator drug
in trials of β blockers.
Law and colleagues also found β blockers to have a specific
action over and above their blood pressure lowering effects in
preventing a recurrence in the first few years after a coronary
heart disease event. Because blood pressure is an important risk
factor for recurrent events in patients with established
cardiovascular disease, as well as those at risk of a first event,
it had seemed counterintuitive that β blockers should be an
unfavoured treatment before a patient has had a coronary event
but a preferred option immediately afterwards. In the longer
term, their benefits were consistent with the degree of blood
pressure lowering and proportionally similar to that seen in
individuals with no prior event.16
Risk of type 2 diabetes
Patients receiving β blockers or thiazides rather than other drugs
such as ACE inhibitors are at higher risk of diabetes. 18But what
is the magnitude of the blood glucose increase; by how much
is the risk of diabetes increased; and, importantly, how does
this affect the risk of cardiovascular events?
In the ASCOT trial, diabetes risk was increased among people
randomised to the atenolol-bendroflumethiazide arm (hazard
ratio for the comparison of groups randomised to amlodipine
rather than atenolol was 0.70, 95% confidence interval 0.63 to
0.78), yet the average absolute difference in blood glucose
concentration was only 0.2 mmol/L (SD 2.08 mmol/L,
P<0.0001).8 The seemingly substantial increase in the risk of
diabetes arises because an average increase in glucose of as
little as 0.2 mmol/L leads to a substantial increase in the
proportion of people marginally exceeding the diagnostic fasting
blood glucose threshold of 7 mmol/L and therefore being
classified as diabetic (fig 3 on bmj.com).
However, the evidence is not compelling that this small average
increase in glucose translates into a shortfall in protection from
stroke or coronary heart disease. In the Asia Pacific Cohort
Studies Collaboration (a participant level meta-analysis of 237
468 people), a decrease in fasting glucose by 1 mmol/L was
associated with a 21 % (18% to 24%) lower incidence of stroke
and a 23% (19% to 27%) lower incidence of ischaemic heart
disease.18 If the association is causal, and assuming a log-linear
relation between glucose and risk of cardiovascular events, an
increase in fasting glucose of 0.2 mmol/L should confer about
a 5% increase in the risk of stroke, which is less than the
differences reported in the recent trials. Moreover, recent
overviews of prospective observational studies indicate that
although the risk of coronary heart disease is linearly and
modestly increased above a fasting glucose value of 5 mmol/L,
the risk of stroke is substantially raised only at fasting glucose
values well above 7 mmol/L (fig 4 in supplementary analysis
on bmj.com). 19-21
Furthermore in the ALLHAT trial (in which 33 357 patients
were randomised to chlortalidone, amlodipine, or lisinopril)
there was a difference in blood glucose of 0.16 mmol/L in the
amlodipinegroup compared with the chlortalidone group, with
an odds ratio for diabetes of 0.73 (0.58 to 0.91). Yet the hazard
ratio for stroke was 0.93 (0.82 to 1.06). There was only a small
blood pressure disparity between the chlortalidone arm and
amlodipine arms (blood pressure difference amlodipine versus
chlortalidone 0.8 mm Hg systolic (P=0.03)/−0.8 mm Hg
diastolic (P<0.001)). This suggests that the observed differences
in risk of stroke in these trials are more likely to be explained
by differences between the treatment arms in blood pressure
rather than glucose. The relevance of the small average increase
in glucose is further questioned by recent trials that indicate that
tight glucose control does not necessarily lead to a reduction in
cardiovascular event rates.
Despite this, NICE cost effectiveness models were based on the
assumption that β blockers provide less protection from stroke
than all other drug classes (not just calcium channel blockers)
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and that any diagnosis of diabetes is associated with twice the
risk of mortality and other cardiovascular disease events
compared with no diabetes. It is not clear whether the known
effects of β blockers in preventing recurrent coronary heart
disease events were modelled in the economic analysis.
How does guidance compare
internationally?
Guidance in the United States published before 2006
recommends diuretics as first line treatment, with β blockers
given equal standing to the other drug classes.24 The European
Society of Hypertension and the European Society of Cardiology
guideline from 2007 also recommends β blockers and thiazide
diuretics as first line options in the absence of contraindications,
except among those with established metabolic syndrome or a
particularly high risk of diabetes.25 However guidance in
Scotland and New Zealand has changed in line with NICE’s
2006 recommendations.
Resolving uncertainty
Network (mixed treatment) meta-analysis was used to evaluate
the comparative efficacy and safety of the main blood pressure
lowering drug classes in relation to cardiovascular events28 and
diabetes,17 but these analyses preceded the recent large influential
trials and meta-analyses. An updated network meta-analysis
that includes efficacy and safety outcomes and which accounts
for blood pressure and glucose differences between treatment
arms could help reduce any remaining uncertainty.
In the meantime, the most recent evidence indicates that the
four classes of drug are more similar than different in their
clinical efficacy and safety and that their effects in combination
are additive, irrespective of mechanism. The initial choice of
drug class and combination could thus rest on price, tolerability,
and specific contraindications in individual patients. This
simplification would benefit healthcare commissioners, doctors,
and patients.
Contributors and sources: RS, JPC, AG, LS, RJM, and ADH are engaged
in research on the primary and secondary prevention of cardiovascular
disease. RS holds a NIHR clinical lectureship in translational medicine.
RS is an honorary specialist registrar and RJM and ADH are honorary
consultants at University College London Hospital cardiovascular risk
clinic. All authors have contributed to the conception, design, analysis,
and interpretation of the data, as well as drafting and critical and final
review of the manuscript.
Competing interests: All authors have completed the ICJME unified
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare no support from
any organisation for the submitted work; LS is supported by aWellcome
Trust Senior Fellowship, ADH has received honorariums for speaking
at courses and meetings on cardiovascular disease prevention, which
were donated in part to charity, has provided non-remunerated advice
to GlaxoSmithKline and London Genetics, and is a member of the JBS3
guidelines development group. RS, RJM and ADH are members of the
British Hypertension Society.
Provenance and peer review: Not commissioned; externally peer
reviewed.
1 Lawes CM, Vander Hoorn S, LawMR, Elliott P, MacMahon S, Rodgers A. Blood pressure
and the global burden of disease 2000. Part II: estimates of attributable burden. J
Hypertens 2006;24:423-30.
2 NICE, British Hypertension Society. NICE clinical guideline 34. Hypertension: management
of hypertension in adults in primary care. 2006. www.nice.org.uk/CG34.
3 Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of
antihypertensive treatment by crossover rotation of four major classes. Lancet
1999;353:2008-13.
4 Belmin J, Levy BI, Michel JB. Changes in the renin-angiotensin-aldosterone axis in later
life. Drugs Aging 1994;5:391-400.
5 Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive
medication on aldosterone and renin concentration in the differential diagnosis of essential
hypertension and primary aldosteronism. Clin Endocrinol 2002;57:457-65.
6 De Bruin RA, Bouhuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation
of a new automated renin assay. Clin Chem 2004;50:2111-6.
7 Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus
monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42
trials. Am J Med 2009;122:290-300.
8 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of
cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril
as required versus atenolol adding bendroflumethiazide as required, in the
Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm (ASCOT-BPLA):
a multicentre randomised controlled trial. Lancet 2005;366:895-906.
9 Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the
treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
10 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence
for use of beta-blockers as first-line therapy for hypertension? Systematic review and
meta-analysis. J Hypertens 2006;24:2131-41.
11 Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of
hypertension: a meta-analysis. CMAJ 2006;174:1737-42.
12 Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, et al. Role of blood
pressure and other variables in the differential cardiovascular event rates noted in the
Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm (ASCOT-BPLA).
Lancet 2005;366:907-13.
13 Staessen JA, BirkenhagerWH. Evidence that new antihypertensives are superior to older
drugs. Lancet 2005;366:869-71.
14 Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with
blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.
15 Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different
regimens to lower blood pressure on major cardiovascular events in older and younger
adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3.
16 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of
cardiovascular disease: meta-analysis of 147 randomised trials in the context of
expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
17 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network
meta-analysis. Lancet 2007;369:201-7.
18 Lawes CM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G, et al. Blood glucose and
risk of cardiovascular disease in the Asia Pacific region.Diabetes Care 2004;27:2836-42.
19 Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers
of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik
prospective study and systematic review. PLoS Med 2010;7:e1000278.
20 Lawlor DA, Fraser A, Ebrahim S, Smith GD. Independent associations of fasting insulin,
glucose, and glycated haemoglobin with stroke and coronary heart disease in older women.
PLoS Med 2007;4:e263.
21 Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes
mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative
meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
22 Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose
levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3
different classes of antihypertensive treatment: a report from the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med
2006;166:2191-201.
23 ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et
al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med 2008;358:2560-72.
24 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh
report of the joint national committee on prevention, detection, evaluation, and treatment
of high blood pressure. Hypertension 2003;42:1206-52.
25 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007
guidelines for the management of arterial hypertension: the task force for the management
of arterial hypertension of the European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
26 Scottish Intercollegiate Guidelines Network. Risk estimatation and the prevention of
cardiovascular disease. Guideline No 97. SIGN, 2007.
27 New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: a
summary resource for primary care practitioners. NZGG, 2009.
28 Psaty BM, Lumley T, Furberg CD, SchellenbaumG, Pahor M, Alderman MH, et al. Health
outcomes associated with various antihypertensive therapies used as first-line agents: a
network meta-analysis. JAMA 2003;289:2534-44.
Accepted: 2 November 2011
Cite this as: BMJ 2011;343:d8078.
© BMJ Publishing Group Ltd 2012
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;343:d8078 doi: 10.1136/bmj.d8078 (Published 13 January 2012) Page 3 of 4
ANALYSIS
Figure
Fig 1 Effect of 2006 NICE/British Hypertension Society guidelines on prescribing rates for all classes of antihypertensive
drugs in England (data from NHS Prescriptions Service)
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